FibroGen, Inc. Files 8-K Reporting Other Events
Ticker: KYNB · Form: 8-K · Filed: Sep 2, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $220 million, $85 million, $135 million, $6.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting, corporate-update
TL;DR
FibroGen filed an 8-K on 8/29/25 for other events and financials. Address: 350 Bay St, SF, CA.
AI Summary
FibroGen, Inc. filed an 8-K on August 29, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 350 Bay Street, Suite 100 #6009, San Francisco, California, 94133.
Why It Matters
This 8-K filing indicates FibroGen, Inc. is providing updates on its corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for other events and financial statements, not indicating any immediate significant financial or operational changes.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
- 350 Bay Street Suite 100 #6009 (address) — Principal Executive Offices
- San Francisco, California (location) — City and State of Principal Executive Offices
- 94133 (zip_code) — Zip Code of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for FibroGen, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 29, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 29, 2025.
Where are FibroGen, Inc.'s principal executive offices located?
FibroGen, Inc.'s principal executive offices are located at 350 Bay Street, Suite 100 #6009, San Francisco, California, 94133.
What is the company's telephone number as listed in the filing?
The company's telephone number, including area code, is 415-978-1200.
What is the Standard Industrial Classification (SIC) code for FibroGen, Inc.?
The Standard Industrial Classification (SIC) code for FibroGen, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-09-02 08:00:29
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
- $220 million — a total consideration of approximately $220 million comprised of $85 million in enterprise
- $85 million — approximately $220 million comprised of $85 million in enterprise value and approximately $
- $135 million — n in enterprise value and approximately $135 million in net cash held in China. The sale to
- $6.0 million — osing is subject to holdbacks of: (i) a $6.0 million hold back to offset final net cash adju
- $4.0 million — ree upon final adjustments), and (ii) a $4.0 million hold back to satisfy any indemnity clai
- $81 million — tanley Tactical Value for approximately $81 million. A copy of the Company's press releas
Filing Documents
- fgen-20250829.htm (8-K) — 52KB
- fgen-ex99_1.htm (EX-99.1) — 18KB
- 0000950170-25-112341.txt ( ) — 178KB
- fgen-20250829.xsd (EX-101.SCH) — 24KB
- fgen-20250829_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On August 29, 2025, FibroGen, Inc. (the "Company") completed the sale of FibroGen International (Hong Kong) Ltd., (including its subsidiaries, "FibroGen China") to AstraZeneca Treasury Limited ("AstraZeneca"), for a total consideration of approximately $220 million comprised of $85 million in enterprise value and approximately $135 million in net cash held in China. The sale to AstraZeneca is made pursuant to the Share Purchase Agreement between the parties, dated February 20, 2025, and follows the fulfillment of all closing conditions. The net cash payable by AstraZeneca at the closing is subject to holdbacks of: (i) a $6.0 million hold back to offset final net cash adjustments which will be released following a customary adjustment process approximately 90 days post-closing (as such time may be extended for the parties to mutually agree upon final adjustments), and (ii) a $4.0 million hold back to satisfy any indemnity claims, which will be released, net of any claims paid or unresolved, nine months after the closing. FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. sold all issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. (including all of its roxadustat assets in China) to AstraZeneca, the Company's long-time commercialization partner for roxadustat in greater China and South Korea. FibroGen retains its rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas Pharma Inc., our collaboration partner in Europe, Japan, and certain other territories. At closing, FibroGen repaid its term loan facility to investment funds managed by Morgan Stanley Tactical Value for approximately $81 million. A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 2, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: September 2, 2025 By: /s/ John Alden John Alden General Counsel